Raptor Pharmaceuticals Corp.

Organization Address
7 Hamilton Lndg, Ste 100
Novato, CA 94949-8283

Organization Phone
(415) 382-8111


Biotech and Pharmaceutical

Drug Discovery and Development

Organization Description
Raptor’s mission is to develop and commercialize life-altering therapeutics that treat debilitating and often fatal diseases. Raptor is a NASDAQ-listed biopharmaceutical company with a product pipeline that may advance therapeutic options for five different indications and includes potential for product launch within the next several months. Raptor's management team consists of repeat entrepreneurs with the experience to build a successful company. The company has active development programs in cystinosis, a rare genetic disease, as well as other genetic and metabolic disorders. Clinical Development Pipeline Raptor is developing its proprietary delayed-release form of cysteamine (DR Cysteamine or RP103) for the potential treatment of: Nephropathic Cystinosis (PDUFA date: April 30, 2013) Huntington’s disease (Phase 2/3) Non-alcoholic Steatohepatitis (NASH) (Phase 2b) Additional clinical program: Convivia™ Preclinical Pipeline Raptor's preclinical pipeline includes novel drug candidates to potentially treat cancers and other diseases. These programs include: HepTide™ for the potential treatment of primary liver cancer and other cancers ADO (cysteamine dioxygenase) inhibitor to potentially improve treatment of diseases for which cysteamine is therapeutic.